Valuation: Shield Therapeutics plc

Market Cap 58.85M 78.69M 70.49M 65.03M 110M 7.49B 112M 776M 309M 3.92B 295M 289M 12.42B P/E 2026 *
367x
P/E 2027 * 7.41x
Enterprise Value 77.3M 103M 92.59M 85.42M 145M 9.84B 147M 1.02B 407M 5.15B 388M 380M 16.32B EV / Sales 2026 *
1.45x
EV / Sales 2027 * 1.1x
Free-Float
38.49%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 day+0.92%
1 week-1.79%
Current month-8.64%
1 month-1.79%
3 months-4.35%
6 months-37.50%
Current year-44.16%
1 week 5.3
Extreme 5.3
5.6
1 month 4.95
Extreme 4.95
6.1
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.5
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/2/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/2/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%-1.79%-19.12%-6.78% 77.62M
+6.63%+5.13%+68.86%+145.20% 1,148B
+1.53%+2.84%+47.48%+89.01% 652B
+1.68%+1.96%+29.16%+109.31% 505B
+0.73%+2.45%+54.26%+68.96% 384B
+3.83%-0.62%+69.01%+42.32% 348B
+2.38%+2.65%+34.31%+57.95% 294B
+2.26%+0.55%+3.92%+28.92% 264B
+1.97%+3.01%+57.91%+76.14% 244B
+4.03%+5.36%+39.76%+116.14% 197B
Average +2.20%+2.00%+38.55%+72.72% 403.72B
Weighted average by Cap. +2.25%+2.89%+50.22%+95.97%

Financials

2026 *2027 *
Net sales 53.48M 71.52M 64.06M 59.1M 100M 6.81B 102M 705M 281M 3.56B 268M 263M 11.29B 69.92M 93.5M 83.75M 77.26M 131M 8.9B 133M 922M 368M 4.66B 351M 343M 14.76B
Net income 258K 345K 309K 285K 482K 32.86M 490K 3.4M 1.36M 17.2M 1.29M 1.27M 54.46M 7.74M 10.36M 9.28M 8.56M 14.48M 986M 14.71M 102M 40.73M 516M 38.86M 38.04M 1.63B
Net Debt 18.45M 24.68M 22.1M 20.39M 34.5M 2.35B 35.06M 243M 97.05M 1.23B 92.61M 90.64M 3.9B 18M 24.07M 21.56M 19.89M 33.65M 2.29B 34.2M 237M 94.66M 1.2B 90.32M 88.4M 3.8B
Projected Income Statement - Annual - Shield Therapeutics plc
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
29/10/26 GBX 5.500 +0.92% 393,611
28/10/26 GBX 5.450 0.00% 48,465
27/10/26 GBX 5.450 -0.91% 545,025
26/10/26 GBX 5.500 0.00% 715,716
23/10/26 GBX 5.500 -1.79% 1,062,274
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Shield Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0550GBP
Average target price
0.1667GBP
Spread / Average Target
+203.04%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shield Therapeutics plc